# US 2012/0252139 A1 · Novel Process

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252139 A1
- Document ID: US20120252139A1
- Status: Published application
- Kind: A1
- Application number: 13/505,474
- Filed: 2010-11-03
- Published: 2012-10-04
- Earliest claimed: 2009-11-05
- Assignees: GlaxoSmithKline LLC
- Inventors: Paul Bamborough; Chun-Wa Chung
- Web page: https://patentgrep.com/patent/US20120252139A1

## CPC

- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- G01N 33/6803: {General methods of protein analysis not limited to specific proteins or families of proteins}
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G01N 2500/10: involving cells
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A process for the identification of compounds with a molecular weight in the range 100 to 750 which inhibit the binding of the first and/or second bromodomains of human BRD-2 to 4 to acetylated lysine residues of their physiological partner proteins which comprises selecting those compounds which are able to: a) form a hydrogen bonding interaction in which the compound accepts a hydrogen bond from the sidechain NH2 group of the asparagine residue found at: BRD-2 BRD-2 BRD-3 BRD-4 BRD-4 BD1 BD2 BD1 BRD-3 BD2 BD1 BD2 ASN156 ASN429 ASN116 ASN391 ASN140 ASN433 or b) accept a water-mediated hydrogen bond in which the compound accepts a hydrogen bond from a water that is itself hydrogen-bonded to the sidechain hydroxyl of the tyrosine residue found at BRD-2 BRD-3 BRD-4 BD1 BRD-2 BD2 BD1 BRD-3 BD2 BD1 BRD-4 BD2 TYR113 TYR386 TYR73 TYR348 TYR97 TYR390 and c) which are also able to form a Van der Waals interaction with a lipophilic binding region of a binding pocket such that one or more heavy atoms of the said compounds lie within a 5 Å range of any of the heavy atoms of the following bromodomain residues which define the binding pocket: BRD-2 BRD-2 BRD-3 BRD-4 BRD-4 BD1 BD2 BD1 BRD-3 BD2 BD1 BD2 TRP97 TRP370 TRP57 TRP332 TRP81 TRP374 PRO98 PRO371 PRO58 PRO333 PRO82 PRO375 ASP161 ASP434 ASP121 GLU396 ASP145 GLU438 ILE162 VAL435 ILE122 VAL397 ILE146 VAL439 MET165 MET438 MET125 MET400 MET149 MET442 pharmaceutical compositions containing such compounds, and their use in therapy.

## Claims

### Claim 1

A process for the identification of compounds with a molecular weight in the range 100 to 750 which inhibit the binding of the first and/or second bromodomains of human BRD-2 to 4 to acetylated lysine residues of their physiological partner proteins which comprises selecting those compounds which are able to:
a) form a hydrogen bonding interaction in which the compound accepts a hydrogen bond from the sidechain NH2 group of the asparagine residue found at:
BRD-2
BRD-2
BRD-3
BRD-3
BRD-4
BRD-4
BD1
BD2
BD1
BD2
BD1
BD2
ASN156
ASN429
ASN116
ASN391
ASN140
ASN433
or
b) accept a water-mediated hydrogen bond in which the compound accepts a hydrogen bond from a water that is itself hydrogen-bonded to the sidechain hydroxyl of the tyrosine residue found at
BRD-2
BRD-2
BRD-3
BRD-3
BRD-4
BRD-4
BD1
BD2
BD1
BD2
BD1
BD2
TYR113
TYR386
TYR73
TYR348
TYR97
TYR390
and
c) which are also able to form a Van der Waals interaction with a lipophilic binding region of a binding pocket such that one or more heavy atoms of the said compounds lie within a 5 Å range of any of the heavy atoms of the following bromodomain residues which define the binding pocket:
BRD-2
BRD-2
BRD-3
BRD-3
BRD-4
BRD-4
BD1
BD2
BD1
BD2
BD1
BD2
TRP97
TRP370
TRP57
TRP332
TRP81
TRP374
PRO98
PRO371
PRO58
PRO333
PRO82
PRO375
ASP161
ASP434
ASP121
GLU396
ASP145
GLU438
ILE162
VAL435
ILE122
VAL397
ILE146
VAL439
MET165
MET438
MET125
MET400
MET149
MET442

### Claim 2

A process for the identification of compounds with a molecular weight in the range 100 to 750 which inhibit the binding of the first and/or second bromodomains of human BRD-2 to 4 to acetylated lysine residues of their physiological partner proteins which comprises selecting those compounds which are able to:
a) form a hydrogen bonding interaction in which the compound accepts a hydrogen bond from the sidechain NH2 group of the asparagine residue found at:
BRD-2
BRD-2
BRD-3
BRD-3
BRD-4
BRD-4
BD1
BD2
BD1
BD2
BD1
BD2
ASN156
ASN429
ASN116
ASN391
ASN140
ASN433
and
b) accept a water-mediated hydrogen bond in which the compound accepts a hydrogen bond from a water that is itself hydrogen-bonded to the sidechain hydroxyl of the tyrosine residue found at
BRD-2
BRD-2
BRD-3
BRD-3
BRD-4
BRD-4
BD1
BD2
BD1
BD2
BD1
BD2
TYR113
TYR386
TYR73
TYR348
TYR97
TYR390
and
c) which are also able to form a Van der Waals interaction with a lipophilic binding region of a binding pocket such that one or more heavy atoms of the said compounds lie within a 5 Å range of any of the heavy atoms of the following bromodomain residues which define the binding pocket:
BRD-2
BRD-2
BRD-3
BRD-3
BRD-4
BRD-4
BD1
BD2
BD1
BD2
BD1
BD2
TRP97
TRP370
TRP57
TRP332
TRP81
TRP374
PRO98
PRO371
PRO58
PRO333
PRO82
PRO375
ASP161
ASP434
ASP121
GLU396
ASP145
GLU438
ILE162
VAL435
ILE122
VAL397
ILE146
VAL439
MET165
MET438
MET125
MET400
MET149
MET442

### Claim 3 (depends on 1, 2)

A process according to either claim 1 or claim 2 wherein step (c) requires the compounds to be able to form a Van der Waals interaction with a lipophilic binding region of a binding pocket such that one or more heavy atoms of the said compounds lie within 7.5 Å of at least one heavy atom of each of the 3 residues listed for a given bromodomain
BRD-2
BRD-2
BRD-3
BRD-3
BRD-4
BRD-4
BD1
BD2
BD1
BD2
BD1
BD2
PRO98
PRO371
PRO58
PRO333
PRO82
PRO375
ASP161
ASP434
ASP121
GLU396
ASP145
GLU438
ILE162
VAL435
ILE122
VAL397
ILE146
VAL439

### Claim 4 (depends on 1, 2, 3)

A process according to any of claims 1 to 3 wherein step (a) and/or (b) is performed first to allow identification of a compound fragment, before step (c) is performed to modify the fragment identified from steps (a) and/or (b) to provide a compound with a molecular weight in the range 100 to 750 which inhibit the binding of the first and/or second bromodomains of human BRD-2 to 4 to acetylated lysine residues of their physiological partner proteins.

### Claim 5 (depends on 1, 2, 3, 4)

A process according to any of claims 1 to 4 for the identification of compounds with a molecular weight in the range 100 to 500.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A compound obtained by the process as claimed in any of claims 1 to 5, or a pharmaceutically acceptable salt or solvate thereof.

### Claim 7 (depends on 6)

A pharmaceutical composition which comprises a compound as claimed in claim 6, or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable carriers, diluents and excipients.

### Claim 8 (depends on 6)

A combination pharmaceutical product comprising a compound as claimed in claim 6, or a pharmaceutically acceptable salt or solvate thereof, together with one or more other therapeutically active agents.

### Claim 9 (depends on 6)

A compound as claimed in claim 6, or a pharmaceutically acceptable salt or solvate thereof, for use in therapy.

### Claim 10 (depends on 6)

A compound as claimed in claim 6, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.

### Claim 11 (depends on 6)

The use of a compound as claimed in claim 6, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.

### Claim 12 (depends on 6)

A method of treating diseases or conditions for which a bromodomain inhibitor is indicated in a subject in need thereof which comprises administering a therapeutically effective amount a compound as claimed in claim 6, or a pharmaceutically acceptable salt or solvate thereof.
